Wednesday, August 23, 2023
Corsano Health, a prominent player in the MedTech sector known for crafting high-quality continuous health monitoring devices, has achieved a significant breakthrough in its smart bracelet line. The latest offering, the CardioWatch 287-2, now incorporates Cuffless Blood Pressure measurements—a remarkable feat.
Certified in alignment with the European Medical Device Regulation (EU-MDR), the CardioWatch 287-2 serves as a wireless remote monitoring solution designed to collect consistent physiological data across diverse settings, including homes and healthcare facilities. It excels in tracking metrics such as heart rate, heart rate variability (R-R interval), respiration rate, activity levels, sleep patterns, ECG readings, SpO2 levels, body temperature, and the newly introduced Blood Pressure readings. Seamlessly transmitting data wirelessly from the device to designated applications or gateways, which then connects to dedicated servers or health clouds, enables systematic storage and comprehensive subsequent analysis.
The foundation of this advancement rests upon Corsano's pioneering Cuffless Non-Invasive Blood Pressure algorithm. Developed since 2019, this algorithm harnesses data from arterial lines and Ambulatory Blood Pressure Monitoring (ABPM) drawn from a substantial cohort of over 500 patients. Rigorous validation, adhering to the ISO 81060-2:2019 standard and the collaborative proclamation by AAMI, ESH, and ISO titled "A Universal Standard for the Validation of Blood Pressure Measuring Devices" (2018), robustly affirms the accuracy and dependability of Corsano's Blood Pressure algorithm. Additional validation processes, encompassing prolonged performance assessments, device orientation, recalibration needs, performance during physical activities, and compatibility with treatments, are actively underway to align with the recommendations set forth by the European Society of Hypertension (ESH).
The validation of Corsano's groundbreaking Cuffless Non-Invasive Blood Pressure algorithm is slated for presentation by the research team from Reinier de Graaf Hospital at the upcoming European Cardiology Congress on August 28, 2023.
Dr. Peter Stas, CEO of Corsano Health, accentuates the transformative potential of the CardioWatch 287-2 in continuous health monitoring. "Corsano Health's CardioWatch 287-2 enables uninterrupted monitoring of vital parameters over extended periods, granting access to raw data crucial for advancing AI and ML technologies. This approach facilitates early anomaly detection by capturing fluctuations that sporadic measurements might overlook. Continuous monitoring holds immense promise in managing chronic conditions like heart disease, with the potential to significantly enhance patient outcomes."